Based in Cambridge and the US and quoted on Nasdaq in the States, Bicycle has presented the first human imaging data validating the potential of MT1-MMP as a novel target in the treatment of cancer. And it has demonstrated the positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use, as well as preclinical data demonstrating optimised BRC radioisotope delivery. Source: Business Weekly 24/10/2024